July 2026 Research Update

This months evidence made it clearer that stiff-person syndrome spectrum disorders often overlap with other autoimmune illnesses, rather than occurring in isolation. Across many studies pooled together, about half of patients had at least 1 additional autoimmune condition, with higher rates in some subtypes and antibody groups. For patients, this frames SPS as part of a wider immune pattern in many people, which can help explain why doctors may ask about other immune-related health problems. [1]

The most commonly reported autoimmune comorbidities were diabetes (including type 1 diabetes and LADA) and autoimmune thyroid disease. Other autoimmune conditions were less common, but still appeared across the combined data, showing that the overlap can involve different organs in different people. This matters because symptoms from a second autoimmune condition can add to day-to-day burden and can complicate the overall health picture. [1]

The review also reported that autoimmune comorbidities were more frequent in PERM (a more severe SPS spectrum form) than in classic SPS, and lower in focal or segmental SPS. It also found higher comorbidity rates in people who were GAD65 antibody-positive than in those who were GAD65 antibody-negative. For patients, this adds context for why antibody results and SPS subtype sometimes come up in conversations about the broader autoimmune risk. [1]

For patients and caregivers, this evidence mainly adds understanding rather than changing treatment choices by itself. It helps clarify that it is common for SPS spectrum disorders to travel with other autoimmune conditions, especially diabetes and thyroid disease, and that this overlap may be more likely in PERM and in GAD65 antibody-positive SPS. What remains uncertain from this summary is how often these comorbidities are recognized early, and how much they directly affect SPS symptoms versus overall health and quality of life. [1]

This month brought a clearer negative result about one proposed electrical test for SPS: it did not reliably distinguish SPS from other groups. That is important because it suggests this specific test, as studied here, may not add much clarity when someone is being evaluated for SPS-like symptoms. For patients, it reinforces that diagnosis often cannot rest on a single specialized measurement. [2]

Researchers measured reflex responses on surface EMG after stimulating nerves in the arm and leg, comparing 11 people with SPS to healthy controls and to people with other neurologic conditions. Some groups showed shorter response times than the SPS group, but there were no consistent differences in how long the responses lasted or whether after-bursts were present. In plain language, the signal was not specific enough to function as a clear SPS vs not-SPS separator in this dataset. [2]

For patients, this finding mainly affects expectations about testing, not treatment. It helps clarify that this kind of reflex testing may not provide a definitive answer on its own, at least as measured in this small study. What remains uncertain is whether other testing approaches, different patient groups, or different ways of analyzing the signals could perform better, since this report does not establish what would work instead. [2]

This months patient reports add to a developing picture: people with severe or hard-to-treat SPS spectrum illness sometimes improve substantially with immune therapies, but care is often highly individualized and evidence is still early. Across these reports, improvements happened in real-world situations where standard options were limited or where multiple immune treatments were combined. For patients, this provides a realistic view of why treatment stories can look different from person to person and why it can be hard to credit one specific drug. [3] [4] [5]

In one person with GlyR1 antibody-positive PERM, repeated courses of IVIg (an immune treatment made from donated antibodies) were reported alongside major functional recovery over time, and the antibody test later became negative. A single salvage dose of ofatumumab (a B-cell depleting antibody treatment) was also given, but the report did not show a clear immediate effect from that dose by itself. This matters because it illustrates both the potential for recovery and the difficulty of separating treatment effects from the natural course and other medical factors. [3]

Another report described a person with anti-GAD65 SPS who improved substantially after a sequence of efgartigimod (a drug that lowers IgG antibodies) followed by ofatumumab, after previous treatments had not worked. The person improved despite persistently high anti-GAD65 antibody levels, suggesting that symptoms and antibody numbers do not always move together in a simple way. For patients, this helps explain why lab results may not perfectly match day-to-day function in some situations. [4]

A small case series of anti-GAD65 related neurologic syndromes also emphasized that people can present with different brain areas involved and may respond differently to treatments such as IVIg, corticosteroids, rituximab, or azathioprine. One person had a mild allergic reaction to rituximab, showing that tolerability can also differ across individuals. For patients, the main message is variability: the same antibody can be linked to different symptoms and different treatment journeys. [5]

For patients and caregivers, these reports may matter most as early signals and as context for why SPS care is often personalized, especially in severe illness or when infections, age, or other conditions limit options. They help clarify that improvement is possible in some individuals with immune-focused approaches, and that antibody levels may not always track closely with symptoms. What remains uncertain is how well these experiences apply to most people with SPS, because they involve very small numbers and overlapping treatments, so they cannot show which specific drug works best or for whom. [3] [4] [5]